Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU ...Middle East

SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the...

Hence then, the article about asieris presents for the first time interim analysis data of oral apl 1202 in combination with pd 1 inhibitor tislelizumab for neoadjuvant treatment of muscle invasive bladder cancer at 2024 asco gu was published today ( Monday 29/01/2024 - 09:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU )

Also on site :

• My Big Family Once Formed the Backbone of My Life. Then, We Discovered My Sister’s Horrific Actions. Now Nothing Is the Same.
• ‘Fire Country’ Announces Major Change After Season 4 Cast Shake-Up
• ‘Beloved’ Woodford Reserve Bourbon Is Back Nationwide